"Survodutide Phase 2 Trial Results"
Drug Updates

Zealand Pharma announces Boehringer Ingelheim survodutide Phase 2 trial shows 83% of adults treated achieved groundbreaking results in liver disease due to MASH, with significant improvements in fibrosis

Zealand Pharma A/S (Nasdaq: ZEAL) today announced that Boehringer Ingelheim has reported that up to 83.0% of adults treated with survodutide (BI 456906) achieved a statistically significant improvement of metabolic dysfunction-associated steatohepatitis (MASH) versus placebo (18.2%) in a Phase 2 trial [response difference: 64.8% (CI 51.1% – 78.6%), p-value (p<0.0001)]. The trial met its primary […]

Brii Biosciences and VBI Vaccines agreements
Drug Updates

Brii Biosciences Announces Agreement to Acquire VBI’s IP Rights in BRII-179 (VBI-2601) and Plans to Initiate Technology Transfer to Expand Clinical and Commercial Supplies

Brii Biosciences Limited (“Brii Bio,” “we,” or the “Company”, stock code: 2137.HK), a biotechnology company developing therapies to improve patient health and choice across diseases with high unmet needs, today announced that it has entered into agreements with VBI Vaccines, Inc. (“VBI”, NASDAQ: VBIV), ensuring expansion and control of future clinical and commercial supplies of BRII-179, a late-stage […]

Wasatch Biolabs DNA Methylation Sequencing Service Launch
Device Digest

Wasatch Biolabs Launches Proprietary Targeted DNA Methylation Sequencing Service for Researchers and Healthcare Providers

Wasatch Biolabs (WBL), a subsidiary of Renew Biotechnologies and a certified Oxford Nanopore Technologies’ laboratory, launches a proprietary Targeted DNA Methylation Sequencing Service for researchers and clinical service providers. The technique is amplification and bisulfite conversion free, effectively bypassing the most common limitations of targeted methylation analysis and enabling WBL to create custom methylation panels that target […]

"HMB-001 Phase 1 Results"
Digital Health News

Hemab Therapeutics Presents Positive Phase 1 Results for HMB-001 in Glanzmann Thrombasthenia at 2024 EAHAD Annual Congress

Hemab Therapeutics, a clinical-stage biotechnology company developing novel prophylactic therapeutics for serious, underserved bleeding and thrombotic disorders, today presented initial results from Phase 1 of its ongoing evaluation of HMB-001. A novel bispecific antibody, HMB-001 is in development as a prophylactic treatment for the bleeding disorder Glanzmann Thrombasthenia (Glanzmann). The data were presented as one of […]

PostEra and Amgen Collaboration - AI in Drug Discovery
Device Digest

PostEra Announces a Research Collaboration with Amgen to Discover Small Molecule Therapeutics using Artificial Intelligence

PostEra, a biotechnology company specializing in artificial intelligence for preclinical drug discovery, today announced a multi-target collaboration with Amgen, a leading biotechnology company. The collaboration will leverage PostEra’s AI platform, Proton, a pioneering innovation in generative chemistry and synthesis-aware design, and Amgen’s drug discovery expertise, to advance up to 5 small molecule programs. Upon a certain […]

Adiso Therapeutics Phase 1b Trial Results
Drug Updates

Adiso Therapeutics Announces Positive Topline Data from Phase 1b Study of ADS051 for the Treatment of Moderate-to-Severe Ulcerative Colitis

Adiso Therapeutics, Inc., a clinical-stage biotechnology company committed to creating medicines that treat inflammatory diseases and improve the lives of patients and their families, today announced positive topline data from its Phase 1b multiple ascending dose (MAD) clinical trial evaluating ADS051 (BT051) in patients with moderate-to-severe ulcerative colitis (UC). The data were presented today at the […]

Scientists working in a laboratory
Drug Updates

ERS Genomics & AlgenScribe Enter Into CRISPR/Cas9 Licensing Agreement

ERS Genomics Limited (‘ERS’) is pleased to announce a new license agreement with AlgenScribe SAS (‘AlgenScribe’). This is a non-exclusive licensing agreement granting AlgenScribe access to the ERS CRISPR/Cas9 patent portfolio. ERS founder, Dr. Emmanuelle Charpentier, won the 2020 Nobel Prize for the discovery of CRISPR/Cas9. The ERS patent portfolio is the definitive collection of […]

Epigenetic Reprogramming for Longevity
Digital Health News

Turn Biotechnologies Co-Founder to Present at Prestigious ARDD Meeting in Copenhagen

Turn Biotechnologies co-founder Vittorio Sebastiano will share company data during a presentation on the potential of epigenetic reprogramming to increase human longevity during this week’s 10th Aging Research and Drug Discovery Meeting (ARDD), the world’s largest longevity forum. Epigenetic reprogramming is prominent at this year’s meeting, which is expected to attract hundreds of scientists and […]

Drug Updates

Genoskin launches MANTIS, a spatial biology imaging platform dedicated to skin immunology

Genoskin, a biotechnology company that leverages live ex vivo human skin to test therapeutic and non-therapeutic products, today announces the launch of MANTIS®, a new spatial biology imaging platform dedicated to skin immunology. This new offer was developed by Dr. Nicolas Gaudenzio and his team at Inserm. Dr. Gaudenzio was recently appointed CSO (Chief Scientific […]

Pandemic Pulse

I2cure BioShield proven 99.9% effective against coronavirus: US Based laboratory proclaims

In the time of the global pandemic, I2cure launched their BioShield in India which is a research of Dr. Jack Kessler (Father of I2) an FDA Compliant, ISO 9001:2015, and WHO GMP certified product. Recently, a study was conducted in compliance with U.S. Environmental Protection Agency Good Laboratory Practice (GLP) which stated that I2Cure demonstrates […]